Cancer Drug Market Overview
Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body. The whole medical research fraternity has prioritized cancer research to find new ways of treatment and analysis. Cancer drugs are used in the treatment of breast cancer, ovarian cancer, pancreatic cancer, kidney cancer, brain tumors, gastric cancer, and other cancers through chemotherapy, surgery, and radiotherapy.
In current times, several regions have occurred as hubs of cancer research, drug development, and medical testing. This key factor has been fuelling the growth of the global Cancer Drug market. Moreover, other factors such as cancer research entities are involved in the development of drugs that directly target cancer cells. This crucial factor primally boosting the growth of the global Cancer Drugs market. Besides, the large focus on biological therapy also enhanced the growth of the global Cancer Drugs market over the last few years.
Additionally, the tremendous efforts of the World Health Organization in promoting cancer research and drug development have also played an important role in boosting the growth of the market. According to World Health Organization, cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths, in 2018. Lung, prostate, colorectal, stomach, and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervical, and thyroid cancer are the most common among women.
On the downside, the high cost of new drug development, combined with the risk of failure and side-effects related to cancer drug therapies, is anticipated to hamper the growth of the Cancer Drugs market. Furthermore, the pursuit of oncologists to find appropriate and correct treatments has also propelled the growth of the market. In addition to this, all forms of cancer drugs introduced are quick to be tested, which further influenced the market’s growth progressively.
Covid-19 Impact on Cancer Drug Market
In addition, the current Cancer Drug Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Cancer Drug Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Cancer Drug Market Segment Overview
Based on Drug Class Type, the Targeted Therapy segment accounted for the largest share in the Cancer Drug market. This can be mainly attributed to the identification of molecular targets of cancer cells. Recent developments in cellular technology and gene therapy have contributed to improving the understanding of tumor cells and their metabolism at the molecular level, hence driving the need for targeted drug therapies for cancer treatment.
According to Indication, the Breast Cancer segment has significant growth in the market. As per data by World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most dominant cancer. In addition, there are more lost disability-adjusted life years by women to breast cancer globally than any other type of cancer. Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life.
Cancer Drug Market, By Drug Class Type
· Chemotherapy
· Targeted Therapy
· Immunotherapy
· Hormonal Therapy
Cancer Drug Market, By Indication
· Lung Cancer
· Stomach Cancer
· Breast Cancer
· Prostate Cancer
· Others
Cancer Drug Market, End-User
· Hospitals
· Clinics
· Others
Cancer Drug Market Regional Overview
Region-wise, North America is expected to account for a maximum share of the global Cancer Drugs market and it maintains its supremacy throughout the forecast period. This can be primarily attributed to the presence of well-developed institutes for cancer research and treatment in this region. Moreover, the cancer drugs market in the Asia Pacific is projected to enlarge at a rapid pace in the forecast period. Major factors such as increasing expenditure on healthcare, rising disposable income, increasing research & development activities, coupled with growing awareness associated with different types of cancers significantly contribute to the development of the market in this region.
Cancer Drug Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Cancer Drug Market Competitor overview
Some key developments and strategies adopted by manufacturers in Cancer Drug are highlighted below.
In August 2021, InxMed (Nanjing) Co., Ltd., a clinical-stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IN10018 for the treatment of platinum-resistant ovarian cancer patients. InxMed owns the global patent and development right of IN10018. The Fast-Track designation for IN10018 underscores the urgent need for new treatment options for platinum-resistant ovarian cancer patients and the significant treatment potential of IN10018, it also further proves the InxMed's world-class translational and clinical development capabilities.
Cancer Drug Market, Key Players
· F. Hoffmann-La Roche AG
· Novartis AG
· Bristol-Myers Squibb Company
· Merck & Co., Inc.
· Johnson & Johnson
· AbbVie Inc.
· Amgen
· Astellas Pharma Inc.
· AstraZeneca PLC
· Pfizer Inc.
Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body. The whole medical research fraternity has prioritized cancer research to find new ways of treatment and analysis. Cancer drugs are used in the treatment of breast cancer, ovarian cancer, pancreatic cancer, kidney cancer, brain tumors, gastric cancer, and other cancers through chemotherapy, surgery, and radiotherapy.
In current times, several regions have occurred as hubs of cancer research, drug development, and medical testing. This key factor has been fuelling the growth of the global Cancer Drug market. Moreover, other factors such as cancer research entities are involved in the development of drugs that directly target cancer cells. This crucial factor primally boosting the growth of the global Cancer Drugs market. Besides, the large focus on biological therapy also enhanced the growth of the global Cancer Drugs market over the last few years.
Additionally, the tremendous efforts of the World Health Organization in promoting cancer research and drug development have also played an important role in boosting the growth of the market. According to World Health Organization, cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in six deaths, in 2018. Lung, prostate, colorectal, stomach, and liver cancer are the most common types of cancer in men, while breast, colorectal, lung, cervical, and thyroid cancer are the most common among women.
On the downside, the high cost of new drug development, combined with the risk of failure and side-effects related to cancer drug therapies, is anticipated to hamper the growth of the Cancer Drugs market. Furthermore, the pursuit of oncologists to find appropriate and correct treatments has also propelled the growth of the market. In addition to this, all forms of cancer drugs introduced are quick to be tested, which further influenced the market’s growth progressively.
Covid-19 Impact on Cancer Drug Market
In addition, the current Cancer Drug Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Cancer Drug Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Cancer Drug Market Segment Overview
Based on Drug Class Type, the Targeted Therapy segment accounted for the largest share in the Cancer Drug market. This can be mainly attributed to the identification of molecular targets of cancer cells. Recent developments in cellular technology and gene therapy have contributed to improving the understanding of tumor cells and their metabolism at the molecular level, hence driving the need for targeted drug therapies for cancer treatment.
According to Indication, the Breast Cancer segment has significant growth in the market. As per data by World Health Organization, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women alive who were diagnosed with breast cancer in the past 5 years, making it the world’s most dominant cancer. In addition, there are more lost disability-adjusted life years by women to breast cancer globally than any other type of cancer. Breast cancer occurs in every country of the world in women at any age after puberty but with increasing rates in later life.
Cancer Drug Market, By Drug Class Type
· Chemotherapy
· Targeted Therapy
· Immunotherapy
· Hormonal Therapy
Cancer Drug Market, By Indication
· Lung Cancer
· Stomach Cancer
· Breast Cancer
· Prostate Cancer
· Others
Cancer Drug Market, End-User
· Hospitals
· Clinics
· Others
Cancer Drug Market Regional Overview
Region-wise, North America is expected to account for a maximum share of the global Cancer Drugs market and it maintains its supremacy throughout the forecast period. This can be primarily attributed to the presence of well-developed institutes for cancer research and treatment in this region. Moreover, the cancer drugs market in the Asia Pacific is projected to enlarge at a rapid pace in the forecast period. Major factors such as increasing expenditure on healthcare, rising disposable income, increasing research & development activities, coupled with growing awareness associated with different types of cancers significantly contribute to the development of the market in this region.
Cancer Drug Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Cancer Drug Market Competitor overview
Some key developments and strategies adopted by manufacturers in Cancer Drug are highlighted below.
In August 2021, InxMed (Nanjing) Co., Ltd., a clinical-stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IN10018 for the treatment of platinum-resistant ovarian cancer patients. InxMed owns the global patent and development right of IN10018. The Fast-Track designation for IN10018 underscores the urgent need for new treatment options for platinum-resistant ovarian cancer patients and the significant treatment potential of IN10018, it also further proves the InxMed's world-class translational and clinical development capabilities.
Cancer Drug Market, Key Players
· F. Hoffmann-La Roche AG
· Novartis AG
· Bristol-Myers Squibb Company
· Merck & Co., Inc.
· Johnson & Johnson
· AbbVie Inc.
· Amgen
· Astellas Pharma Inc.
· AstraZeneca PLC
· Pfizer Inc.
Cancer Drug Market Study Global Market Analysis, Insights and Forecast, 2020-2027
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Cancer Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Drug Class Type
- 5.2.1. Chemotherapy
- 5.2.2. Targeted Therapy
- 5.2.3. Immunotherapy
- 5.2.4. Hormonal Therapy
- 5.3. Market Analysis, Insights and Forecast – By Indication
- 5.3.1. Lung Cancer
- 5.3.2. Stomach Cancer
- 5.3.3. Breast Cancer
- 5.3.4. Prostate Cancer
- 5.3.5. Others
- 5.4. Market Analysis, Insights and Forecast – By End-User
- 5.4.1. Hospitals
- 5.4.2. Clinics
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast – By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America, Middle East and Africa
6. North America Cancer Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Drug Class Type
- 6.2.1. Chemotherapy
- 6.2.2. Targeted Therapy
- 6.2.3. Immunotherapy
- 6.2.4. Hormonal Therapy
- 6.3. Market Analysis, Insights and Forecast – By Indication
- 6.3.1. Lung Cancer
- 6.3.2. Stomach Cancer
- 6.3.3. Breast Cancer
- 6.3.4. Prostate Cancer
- 6.3.5. Others
- 6.4. Market Analysis, Insights and Forecast – By End-User
- 6.4.1. Hospitals
- 6.4.2. Clinics
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast – By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Cancer Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Drug Class Type
- 7.2.1. Chemotherapy
- 7.2.2. Targeted Therapy
- 7.2.3. Immunotherapy
- 7.2.4. Hormonal Therapy
- 7.3. Market Analysis, Insights and Forecast – By Indication
- 7.3.1. Lung Cancer
- 7.3.2. Stomach Cancer
- 7.3.3. Breast Cancer
- 7.3.4. Prostate Cancer
- 7.3.5. Others
- 7.4. Market Analysis, Insights and Forecast – By End-User
- 7.4.1. Hospitals
- 7.4.2. Clinics
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast – By Country
- 7.5.1. UK
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Russia
- 7.5.7. Rest of Europe
8. Asia Pacific Cancer Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Drug Class Type
- 8.2.1. Chemotherapy
- 8.2.2. Targeted Therapy
- 8.2.3. Immunotherapy
- 8.2.4. Hormonal Therapy
- 8.3. Market Analysis, Insights and Forecast – By Indication
- 8.3.1. Lung Cancer
- 8.3.2. Stomach Cancer
- 8.3.3. Breast Cancer
- 8.3.4. Prostate Cancer
- 8.3.5. Others
- 8.4. Market Analysis, Insights and Forecast – By End-User
- 8.4.1. Hospitals
- 8.4.2. Clinics
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast – By Country
- 8.5.1. China
- 8.5.2. India
- 8.5.3. Japan
- 8.5.4. Australia
- 8.5.5. South East Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Cancer Drug Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Drug Class Type
- 9.2.1. Chemotherapy
- 9.2.2. Targeted Therapy
- 9.2.3. Immunotherapy
- 9.2.4. Hormonal Therapy
- 9.3. Market Analysis, Insights and Forecast – By Indication
- 9.3.1. Lung Cancer
- 9.3.2. Stomach Cancer
- 9.3.3. Breast Cancer
- 9.3.4. Prostate Cancer
- 9.3.5. Others
- 9.4. Market Analysis, Insights and Forecast – By End-User
- 9.4.1. Hospitals
- 9.4.2. Clinics
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast – By Country
- 9.5.1. Brazil
- 9.5.2. Saudi Arabia
- 9.5.3. UAE
- 9.5.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. F. Hoffmann-La Roche AG
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Novartis AG
- 10.6. Bristol-Myers Squibb Company
- 10.7. Merck & Co., Inc.
- 10.8. Johnson & Johnson
- 10.9. AbbVie Inc.
- 10.10. Amgen
- 10.11. Astellas Pharma Inc.
- 10.12. AstraZeneca PLC
Research Process
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
